Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk

Completed

Conditions studied: Type 2 Diabetes Mellitus, Obesity, Overweight

In brief

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Key facts

Study ID

NCT07619495

Run by

Brigham and Women's Hospital

People needed

120000

Starts

2026-01-20

Expected to finish

2026-06-01

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women aged 18 years or older
• History of myocardial infarction, stroke, any surgical or percutaneous revascularization procedure
• Use of antihypertensive or lipid-lowering drugs
• Coronary, carotid, or peripheral artery disease
• BMI greater than or equal to 25.0 mg/m2
• Type 2 diabetes

You may not qualify if…

• Medullary thyroid carcinoma
• MEN syndrome type 2
• Malignancy
• Type 1 diabetes
• Secondary diabetes
• End-stage renal disease or dialysis
• Uncontrolled diabetic retinopathy or maculopathy
• Pregnancy
• History of bariatric surgery
• Prior use of pramlintide or any GLP-1-RA, except semaglutide or dulaglutide
• Cardiovascular event or intervention in the last 7 days

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.